Navigation Links
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
Date:9/6/2011

SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday September 12, 2011 at 2:25 p.m. Eastern time, in the Metropolitan East Salon at the Waldorf=Astoria Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates.  The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere®, which recently went off-patent.  The Company is evaluating its Exelbine program following the complete response letter it received from the FDA.  More information can be found on the Company's web site at www.adventrx.com.  


'/>"/>
SOURCE ADVENTRX Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Provides Update on All Three Pipeline Products
2. ADVENTRX Reports Second Quarter 2011 Financial Results
3. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
4. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
5. ADVENTRX Reports First Quarter 2011 Financial Results
6. ADVENTRX Completes Acquisition of SynthRx
7. ADVENTRX Pharmaceuticals Provides Update on ANX-514
8. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
9. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
10. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
11. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology:
(Date:12/5/2016)... Diego, CA (PRWEB) , ... December 05, 2016 , ... ... seen and heard the dangers and downsides of patients who do not do their ... The field of cosmetic dermatology is in the midst of a renaissance and every ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):